Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2014

View Archived Issues

Telik seeks shareholder approval of proposals to transition to MabVax Therapeutics

Delay to Pernix's acquisition of U.S. Treximet rights

MediciNova reports data for MN-001 from advanced NASH mouse model

Ampio Pharmaceuticals reports data from open-label portion of osteoarthritis study

NeuroDerm's ND-0612H eligible for EMA's centralized procedure

IntelliCell BioSciences files pre-IND with FDA for osteoarthritis study

Galapagos delivers second drug candidate in osteoarthritis alliance with Servier

Anti-T-cell receptor MAb investigated for inducing immunotherapeutic potential

Novel human anti-CD83 MAb shows potential for GVHD

New LPA1 receptor antagonists prepared at InterMune

Jazz Pharmaceuticals completes acquisition of rights to defibrotide in the Americas

Focus on Ebola: New strategies in discovery and design of therapies against the lethal disease

HMG-1 identified as an early biomarker of functional recovery after kidney transplantation

Polish scientists patent new helquat derivatives for cancer

Cannabis Science begins preclinical studies on cannabinoid formulations in neurological diseases

Scientists at Roche and Genentech design new DLK inhibitors for neurodegenerative disorders

Galapagos synthesizes new JAK inhibitors

Cytori Therapeutics provides update on ATHENA trials

Aurigene Discovery Technologies reports new Nampt inhibitors

NanoString Technologies receives approval in Australia for breast cancer assay

E.U. approves Roche's Avastin for platinum-resistant recurrent ovarian cancer

Eisai reflects on accomplishments of first quarter of fiscal 2014

MMRGlobal to grant royalty-free licenses to universities to research Ebola therapies

Oxford Immunotec acquires Boulder Diagnostics assets

Boehringer Ingelheim returns PGE2 inhibitor program to Orexo

CTI BioPharma's pacritinib receives FDA fast track status for myelofibrosis

FDA approves oritavancin for acute bacterial skin and skin structure infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...